Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | EIF4E | P06730 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | TOP1 | P11387 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | THPO | P40225 | 1/20 | 0.51 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.51 |
| ▸ | ATIC | P31939 | 2/20 | 0.41 |
| ▸ | FBP1 | P09467 | 1/20 | 0.41 |
| ▸ | PNP | P00491 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6913779 | 0.89 | LMNA (0.54) | LMNASMN1; SMN2ADORA1ALDH1A1GLA | |
| SCHEMBL5897238 | 0.86 | LMNA (0.69) | LMNASMN1; SMN2ADORA1ALDH1A1GLA | |
| SCHEMBL6918155 | 0.85 | LMNA (0.52) | LMNASMN1; SMN2ADORA1ALDH1A1GLA | |
| SCHEMBL6908769 | 0.85 | LMNA (0.51) | LMNASMN1; SMN2ADORA1ALDH1A1GLA | |
| SCHEMBL6913903 | 0.79 | LMNA (0.54) | LMNASMN1; SMN2ADORA1ALDH1A1GLA | |
| Ribavirin Monophosphate SCHEMBL11202379 | 0.77 | LMNA (0.69) | LMNASMN1; SMN2ADORA1ALDH1A1GLA | |
| Ribavirin Monophosphate SCHEMBL10882076 | 0.77 | LMNA (0.69) | LMNASMN1; SMN2ADORA1ALDH1A1GLA | |
| Ribavirin Monophosphate SCHEMBL1508870 | 0.77 | LMNA (0.69) | LMNASMN1; SMN2ADORA1ALDH1A1GLA | |
| Ribavirin Monophosphate SCHEMBL12727825 | 0.77 | LMNA (0.69) | LMNASMN1; SMN2ADORA1ALDH1A1GLA | |
| SCHEMBL24024493 | 0.77 | LMNA (0.62) | LMNASMN1; SMN2ADORA1ALDH1A1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040023901-A1 | Nucleoside 5'-monophosphate mimics and their prodrugs | BIOTA HOLDINGS LIMITED (AU) | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023901-A1 | Nucleoside 5'-monophosphate mimics and their prodrugs | MTAP, ENTPD5, PNP | LMNA 4394/4885SMN1; SMN2 2624/4885ADORA1 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.